Table 2 Laboratory findings of patients between RMPP combined with PB group and RMPP group in the development dataset
Laboratory information | Patients (n = 374) | RMPP combined with PB (n = 137) | RMPP (n = 237) | P |
|---|---|---|---|---|
WBC (× 109/L) | 7.4 (5.9–9.4) | 7.4 (5.8–9.3) | 7.4 (5.9–9.5) | 0.661 |
N% | 68.6 (60.0–76.0) | 72.0 (65.0–78.4) | 67.0 (57.1–73.1) | 0.000 |
L% | 22.0 (16.8–29.3) | 20.0 (15.0–25.0) | 24.3 (17.4–31.6) | 0.000 |
PLT (× 109/L) | 267.0 (221.0–335.3) | 249.0 (205.0–311.0) | 279.0 (232.0–356.5) | 0.000 |
ESR (mm/h) | 29.5 (22.0–40.0) | 30.0 (22.0–41.0) | 29.0 (23.0–40.0) | 0.841 |
CRP (mg/L) | 25.9 (11.7–46.0) | 32.8 (18.0–58.8) | 22.6 (9.7–39.4) | 0.000 |
PCT (ng/mL) | 0.16 (0.10–0.33) | 0.30 (0.10–0.60) | 0.12 (0.07–0.24) | 0.000 |
IL-6 (pg/mL) | 28.6 (16.4–52.3) | 44.0 (27.3–78.9) | 22.5 (14.5–38.4) | 0.000 |
La (mol/L) | 2.6 (2.1–3.1) | 2.5 (2.1–3.1) | 2.6 (2.1–3.1) | 0.459 |
AST (U/L) | 31.0 (25.0–44.0) | 39.0 (29.0–59.0) | 30.0 (24.0–39.0) | 0.000 |
ALT (U/L) | 15.0 (12.0–24.0) | 16.0 (12.0–28.5) | 14.0 (11.0–20.0) | 0.007 |
CK (U/L) | 99.0 (67.0–184.3) | 122.0 (73.5–245.5) | 94.0 (66.0–147.5) | 0.003 |
CKMB (U/L) | 4.0 (3.7–4.0) | 4.0 (3.0–4.0) | 4.0 (4.0–4.0) | 0.335 |
LDH (U/L) | 427.0 (333.8–560.5) | 483.0 (375.0–641.5) | 392.0 (313.5–513.0) | 0.000 |
FER (ng/L) | 132.7 (89.6–227.4) | 142.0 (74.2–261.3) | 132.2 (98.3–196.5) | 0.639 |
APTT (S) | 29.5 (26.2–32.9) | 30.1 (26.1–33.9) | 29.1 (26.4–32.6) | 0.262 |
FG (g/L) | 4.1 (3.6–4.6) | 4.2 (3.7–4.7) | 4.0 (3.7–4.5) | 0.161 |
D-dimer (mg/L) | 0.2 (0.1–0.4) | 0.2 (0.1–0.6) | 0.1 (0.1–0.3) | 0.000 |
IgE (IU/L) | 94.7 (39.7–242.3) | 108.0 (38.9–260.9) | 89.8 (40.2–227.7) | 0.586 |